

POSTER PRESENTATION

Open Access

Assessment of troglitazone induced liver toxicity in a dynamically perfused two-organ Micro-Bioreactor system

Eva-Maria Materne¹, Caroline Frädrieh¹, Reyk Horland¹, Silke Hoffmann¹, Sven Brincker¹, Alexandra Lorenz¹, Mathias Busek², Frank Sonntag², Udo Klotzbach², Roland Lauster¹, Uwe Marx¹, Ilka Wagner^{1*}

From 23rd European Society for Animal Cell Technology (ESACT) Meeting: Better Cells for Better Health Lille, France. 23-26 June 2013

Background

The ever-growing amount of new substances released to the market and the limited predictability of current *in vitro* test systems has led to an ample need for new substance testing solutions. Many drugs like troglitazone, that had to be removed from the market due to drug induced liver injury, show their toxic potential only after chronic long term exposure. But for long-term multiple dosing experiments, a controlled microenvironment is pivotal, as even minor alterations in extracellular conditions may greatly influence the cell physiology. Within our research program, we focused on the generation of a micro-engineered bioreactor, which can be dynamically perfused by an on-chip pump and combines at least two culture spaces for multi-organ applications. This circulatory systems better mimics the *in vivo* conditions of primary cell cultures and assures steadier, more quantifiable extracellular signaling to the cells.

Materials and methods

Liver microtissues (aggregates of HepaRG+human hepatic stellate cells) and skin biopsies were cultured in separate inserts of a 96-well Transwell[®] unit (Corning), which were hung inside the chip with the membrane fitting directly over the circuit. The tissues were cultivated either air/liquid interfaced (skin) or submerged in media (liver equivalent) for a culture period of 28 days. Exposing the tissues to troglitazone, the cultures were cultured for one day in normal medium and were, subsequently, exposed to 0 μ M, 5 μ M and 50 μ M troglitazone, respectively for


further 6 days. Application of troglitazone was repeated at 12 h intervals simultaneously with the medium change. In a further experiment co-cultures of liver and skin equivalents were cultured in a fully vascularized chip. Therefore, HDMECs isolated from human foreskin were seeded into the microfluidic channel system using a syringe. After even cell infusion inside the circuit the device was incubated in 5% CO₂ at 37°C under static conditions for 3 h to allow the cells to attach to the channel walls. A frequency of 0.476 Hz was applied for continuous dynamic operation, after 10 days of monoculture, skin and liver tissue were added for co-cultivation for another 15 days.

Results

Co-cultures of human artificial liver microtissues and skin biopsies have successfully proven the long-term performance of the novel microfluidic multi-organ-chip device. The metabolic activity of the co-culture analysed in media supernatants reached a steady state at day 7 of co-culture and stayed constant for the rest of the culture period (Figure 1A). Furthermore, the co-cultures revealed a dose-dependent response to a 6-day exposure to the toxic substance troglitazone. Liver microtissues showed sensitivity at different molecular levels. LDH levels measured in the media supernatants increased significantly with increasing troglitazone concentration (Figure 1B). Furthermore, an induction of Cyp450 3A4 levels on RNA level were observed (Figure 1C). In addition, a robust procedure applying pulsatile shear stress has been established to cover all fluid contact surfaces of the system with a functional, tightly closed layer of HDMECs and co-cultivation of liver, skin and endothelial cells for 15 days was successful.

* Correspondence: ilka.wagner@tu-berlin.de

¹TU Berlin, Institute for Biotechnology, Faculty of Process Science and Engineering, Gustav-Meyer-Allee 25, 13355 Berlin, Germany
Full list of author information is available at the end of the article



Conclusion

A unique chip-based tissue culture platform has been developed enabling the testing of drugs or chemicals on a set of miniaturized human organs. This “human-on-a-chip” platform is designed to generate high quality *in vitro* data predictive of substance safety in humans. Tissue co-cultures can be exposed to pharmaceutical substances at regimens relevant to respective guidelines, currently used for subsystemic substance testing in animals.

Acknowledgements

The work has been funded by the German Federal Ministry for Education and Research, GO-Bio Grand No. 0315569.

Authors' details

¹TU Berlin, Institute for Biotechnology, Faculty of Process Science and Engineering, Gustav-Meyer-Allee 25, 13355 Berlin, Germany. ²Fraunhofer IWS Dresden, Winterbergstraße 28, 01277 Dresden, Germany.

Published: 4 December 2013

doi:10.1186/1753-6561-7-S6-P71

Cite this article as: Materne et al.: Assessment of troglitazone induced liver toxicity in a dynamically perfused two-organ Micro-Bioreactor system. *BMC Proceedings* 2013 7(Suppl 6):P71.